Abstract
We described pregnancy outcomes in Crohn's disease (CD) patients enrolled in the TREAT Registry who received infliximab before, or during pregnancy and those not treated with infliximab or any biologic agent. In the TREAT Registry (1999-2012), pregnancy outcomes were analyzed from maternal and paternal patients exposed to infliximab ≤365 days (gestational exposure), >365 days (pre-gestational exposure) of pregnancy outcome or without infliximab exposure (non-biologic exposed). "Healthy infants" were defined as those with no congenital abnormalities, neonatal complications (e.g., jaundice, prematurity, heart murmur, cortical vision/fine motor delay, cardiac failure, hemophilia, or torticollis), prolonged hospitalization, or those who received no special treatment. Disease activity and concomitant medications were also evaluated. Overall, 92.3% (324/351) of pregnancies had known outcomes. The majority of both maternal pregnancies (92.6, 91.2, and 87.8%) and partner outcomes (92.7, 93.8, and 91.7%) resulted in live births of healthy infants across gestational, pre-gestational, and non-biologic exposure groups, respectively. Among these, rates of neonatal complications were low for both maternal (6.2, 7.0, and 8.5%), and partner ou...Continue Reading
References
Sep 14, 1999·American Journal of Medical Genetics·S L Carmichael, G M Shaw
Mar 12, 2004·Reproductive Toxicology·Chamutal GurAsher Ornoy
Dec 2, 2004·The American Journal of Gastroenterology·Jeffry A KatzGary R Lichtenstein
May 9, 2006·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Gary R LichtensteinWilliam J Sandborn
Dec 23, 2006·Gut·J CornishP P Tekkis
Feb 21, 2008·Alimentary Pharmacology & Therapeutics·S O'Donnell, C O'Morain
Jan 29, 2009·The American Journal of Gastroenterology·Gary R LichtensteinUNKNOWN Practice Parameters Committee of American College of Gastroenterology
Nov 4, 2009·Inflammatory Bowel Diseases·Javier P Gisbert
Jun 22, 2010·Inflammatory Bowel Diseases·Maria Chaparro, Javier P Gisbert
Sep 30, 2010·Birth Defects Research. Part A, Clinical and Molecular Teratology·Samantha E ParkerUNKNOWN National Birth Defects Prevention Network
Dec 3, 2010·Journal of Crohn's & Colitis·R E MountifieldJ M Andrews
Dec 22, 2010·Journal of Crohn's & Colitis·Christian MottetUNKNOWN EPACT II Study Group
Aug 6, 2011·Alimentary Pharmacology & Therapeutics·A BortoliUNKNOWN European Crohn-Colitis Organisation (ECCO) Study Group of Epidemiologic Committee (EpiCom)
Aug 15, 2012·The American Journal of Gastroenterology·Gary R LichtensteinWilliam J Sandborn
Jan 16, 2013·The American Journal of Gastroenterology·M J CasanovaJ P Gisbert
Mar 6, 2013·The American Journal of Gastroenterology·Sarah Sheibani, Uma Mahadevan
Jan 8, 2014·The American Journal of Gastroenterology·Gary R LichtensteinWilliam J Sandborn
Aug 29, 2014·Alimentary Pharmacology & Therapeutics·P Deepak, D J Stobaugh
Nov 20, 2014·Expert Opinion on Drug Safety·Nabeel KhanGary R Lichtenstein
Apr 18, 2015·Birth Defects Research. Part A, Clinical and Molecular Teratology·April L DawsonUNKNOWN National Birth Defects Prevention Study
Dec 22, 2015·Gastroenterology·Geoffrey C NguyenUNKNOWN Canadian Association of Gastroenterology
Dec 31, 2015·World Journal of Gastroenterology : WJG·Ioannis AndroulakisMaria Gazouli
Oct 23, 2016·Gastroenterology·Uma MahadevanChristina D Chambers
Mar 28, 2017·Inflammatory Bowel Diseases·Heidi KammerlanderBente Nørgård
Citations
Oct 20, 2018·The American Journal of Gastroenterology·Eric J Mao, Uma Mahadevan
Nov 2, 2019·Inflammatory Bowel Diseases·Brindusa TrutaBashar Safar
Nov 7, 2019·Expert Opinion on Biological Therapy·Ciro RomanoGiovanna Cuomo
Feb 6, 2020·Pharmacoepidemiology and Drug Safety·Gabriella BrömsFredrik Granath
May 20, 2020·Expert Review of Gastroenterology & Hepatology·Ferdinando D'AmicoSilvio Danese
Jul 8, 2020·Inflammatory Bowel Diseases·Walter ReinischSilvio Danese
Aug 4, 2020·Human Reproduction Update·L F Perez-GarciaB Te Winkel
Jan 30, 2020·Rheumatology International·Oguz Abdullah UyarogluUmut Kalyoncu
May 30, 2020·Inflammatory Bowel Diseases·Kristel K LeungVivian Huang
Aug 28, 2020·Drugs·N GhalandariH J M J Crijns
Nov 5, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Anja GeldhofDanielle Coppola
Mar 3, 2019·The Journal of Rheumatology·Mihaela C MicuRuxandra Ionescu
Jan 9, 2020·Alimentary Pharmacology & Therapeutics·Parul TandonVivian Huang
Jun 14, 2019·Therapeutic Advances in Gastroenterology·Sarah E ShannahanMark A Peppercorn
Oct 21, 2020·United European Gastroenterology Journal·Ana-Marija GrišićCasper Steenholdt
Jan 8, 2021·Expert Opinion on Drug Safety·Robyn LaubeRupert W Leong
Sep 16, 2020·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Ole Haagen NielsenCynthia Maxwell
Jan 15, 2021·Expert Review of Gastroenterology & Hepatology·Daniela Guerrero Vinsard, Sunanda V Kane
Feb 27, 2021·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Tim RaineAmy C Foulkes
Apr 6, 2021·Journal of Gastroenterology and Hepatology·Réme Mountifield
Mar 22, 2021·Gastroenterology·Joseph MeserveSiddharth Singh
Apr 30, 2021·Frontline Gastroenterology·Christian P SelingerTracey Glanville
Apr 18, 2021·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Sheri Volger, Ellen Scherl
May 15, 2021·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Ole Haagen NielsenCarsten Bogh Juhl
Jun 15, 2021·Frontiers in Pharmacology·Asmaa BeltagyPier Luigi Meroni
Aug 25, 2021·Inflammatory Bowel Diseases·Gurpreet MalhiVivian Huang
Dec 24, 2021·Medicine·Maria Cecília de AragãoLigia Yukie Sassaki